Cargando…

Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan

Background: For non-dialysis patients with hyperlipidemia, statins may provide clinical benefits in reducing mortality risk; however, the optimal treatment for dialysis patients with hyperlipidemia remains debatable. We evaluated the mortality risks for hyperlipidemic patients with renal disorders a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Fung-Chang, Jong, Ying-Chin, Muo, Chih-Hsin, Hsu, Chih-Cheng, Tsai, Wen-Chen, Hsu, Yueh-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930832/
https://www.ncbi.nlm.nih.gov/pubmed/35308209
http://dx.doi.org/10.3389/fphar.2022.815882
_version_ 1784671121612734464
author Sung, Fung-Chang
Jong, Ying-Chin
Muo, Chih-Hsin
Hsu, Chih-Cheng
Tsai, Wen-Chen
Hsu, Yueh-Han
author_facet Sung, Fung-Chang
Jong, Ying-Chin
Muo, Chih-Hsin
Hsu, Chih-Cheng
Tsai, Wen-Chen
Hsu, Yueh-Han
author_sort Sung, Fung-Chang
collection PubMed
description Background: For non-dialysis patients with hyperlipidemia, statins may provide clinical benefits in reducing mortality risk; however, the optimal treatment for dialysis patients with hyperlipidemia remains debatable. We evaluated the mortality risks for hyperlipidemic patients with renal disorders associated with statin therapy (ST), using the insurance claims data of Taiwan. Methods: From hyperlipidemic patients diagnosed in 2000–2011, we identified 555,153 patients receiving statin treatment for at least 90 days continuously and 1,141,901 non-statin users, and then randomly selected, from both groups, the propensity score-matched subcohorts of statin users and nonusers in a 1:1 pair by renal function: 415,453 pairs with normal renal function , 43,632 pairs with chronic kidney disease (CKD), and 3,624 pairs with end-stage renal disease (ESRD). We compared the mortalities, by the end of 2016, from all causes, cancer, heart disease, and septicemia between statin users and non-users and between hydrophilic-statin users and lipophilic-statin users. The Cox method estimated ST users to non-user hazard ratios. The time-dependent model was also conducted as sensitivity analysis. Results: The mean ages were 58.7 ± 10.7, 64.2 ± 10.7, and 62.2 ± 10.8 years in normal renal function, CKD, and ESRD groups, respectively. Compared with non-users, statin users had reduced mortality risks from all causes for 32%–38%, from cancer for 37%–46%, from heart disease for 6%–24%, and from septicemia for 17%–21% in all three renal groups. The hydrophilic statin therapy was superior than the lipophilic statin therapy, particularly for reducing deaths from all-causes and cancer. The results under the time-dependent model were similar. Conclusion: Statin therapy is associated with reduced all-causes and non-cardiovascular mortality in ESRD patients.
format Online
Article
Text
id pubmed-8930832
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89308322022-03-19 Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan Sung, Fung-Chang Jong, Ying-Chin Muo, Chih-Hsin Hsu, Chih-Cheng Tsai, Wen-Chen Hsu, Yueh-Han Front Pharmacol Pharmacology Background: For non-dialysis patients with hyperlipidemia, statins may provide clinical benefits in reducing mortality risk; however, the optimal treatment for dialysis patients with hyperlipidemia remains debatable. We evaluated the mortality risks for hyperlipidemic patients with renal disorders associated with statin therapy (ST), using the insurance claims data of Taiwan. Methods: From hyperlipidemic patients diagnosed in 2000–2011, we identified 555,153 patients receiving statin treatment for at least 90 days continuously and 1,141,901 non-statin users, and then randomly selected, from both groups, the propensity score-matched subcohorts of statin users and nonusers in a 1:1 pair by renal function: 415,453 pairs with normal renal function , 43,632 pairs with chronic kidney disease (CKD), and 3,624 pairs with end-stage renal disease (ESRD). We compared the mortalities, by the end of 2016, from all causes, cancer, heart disease, and septicemia between statin users and non-users and between hydrophilic-statin users and lipophilic-statin users. The Cox method estimated ST users to non-user hazard ratios. The time-dependent model was also conducted as sensitivity analysis. Results: The mean ages were 58.7 ± 10.7, 64.2 ± 10.7, and 62.2 ± 10.8 years in normal renal function, CKD, and ESRD groups, respectively. Compared with non-users, statin users had reduced mortality risks from all causes for 32%–38%, from cancer for 37%–46%, from heart disease for 6%–24%, and from septicemia for 17%–21% in all three renal groups. The hydrophilic statin therapy was superior than the lipophilic statin therapy, particularly for reducing deaths from all-causes and cancer. The results under the time-dependent model were similar. Conclusion: Statin therapy is associated with reduced all-causes and non-cardiovascular mortality in ESRD patients. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8930832/ /pubmed/35308209 http://dx.doi.org/10.3389/fphar.2022.815882 Text en Copyright © 2022 Sung, Jong, Muo, Hsu, Tsai and Hsu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sung, Fung-Chang
Jong, Ying-Chin
Muo, Chih-Hsin
Hsu, Chih-Cheng
Tsai, Wen-Chen
Hsu, Yueh-Han
Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
title Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
title_full Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
title_fullStr Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
title_full_unstemmed Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
title_short Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan
title_sort statin therapy for hyperlipidemic patients with chronic kidney disease and end-stage renal disease: a retrospective cohort study based on 925,418 adults in taiwan
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930832/
https://www.ncbi.nlm.nih.gov/pubmed/35308209
http://dx.doi.org/10.3389/fphar.2022.815882
work_keys_str_mv AT sungfungchang statintherapyforhyperlipidemicpatientswithchronickidneydiseaseandendstagerenaldiseasearetrospectivecohortstudybasedon925418adultsintaiwan
AT jongyingchin statintherapyforhyperlipidemicpatientswithchronickidneydiseaseandendstagerenaldiseasearetrospectivecohortstudybasedon925418adultsintaiwan
AT muochihhsin statintherapyforhyperlipidemicpatientswithchronickidneydiseaseandendstagerenaldiseasearetrospectivecohortstudybasedon925418adultsintaiwan
AT hsuchihcheng statintherapyforhyperlipidemicpatientswithchronickidneydiseaseandendstagerenaldiseasearetrospectivecohortstudybasedon925418adultsintaiwan
AT tsaiwenchen statintherapyforhyperlipidemicpatientswithchronickidneydiseaseandendstagerenaldiseasearetrospectivecohortstudybasedon925418adultsintaiwan
AT hsuyuehhan statintherapyforhyperlipidemicpatientswithchronickidneydiseaseandendstagerenaldiseasearetrospectivecohortstudybasedon925418adultsintaiwan